Rekah Pharmaceutical Valuation
| REKA Stock | ILA 1,499 110.00 7.92% |
At this time, the company appears to be overvalued. Rekah Pharmaceutical holds a recent Real Value of 1217.79 per share. The prevailing price of the company is 1499.0. Our model determines the value of Rekah Pharmaceutical from analyzing the company fundamentals such as Return On Equity of 0.0222, operating margin of 0.05 %, and Shares Outstanding of 11.41 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Rekah Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Rekah Pharmaceutical is based on 3 months time horizon. Increasing Rekah Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Rekah Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rekah Stock. However, Rekah Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1499.0 | Real 1217.79 | Hype 1499.0 | Naive 1458.44 |
The real value of Rekah Stock, also known as its intrinsic value, is the underlying worth of Rekah Pharmaceutical Company, which is reflected in its stock price. It is based on Rekah Pharmaceutical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Rekah Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Rekah Pharmaceutical Industry helps investors to forecast how Rekah stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rekah Pharmaceutical more accurately as focusing exclusively on Rekah Pharmaceutical's fundamentals will not take into account other important factors: Rekah Pharmaceutical Total Value Analysis
Rekah Pharmaceutical Industry is at this time forecasted to have takeover price of 316.92 M with market capitalization of 193.93 M, debt of 101.23 M, and cash on hands of 31.61 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Rekah Pharmaceutical fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
316.92 M | 193.93 M | 101.23 M | 31.61 M |
Rekah Pharmaceutical Investor Information
About 37.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rekah Pharmaceutical last dividend was issued on the 6th of April 2022. Based on the analysis of Rekah Pharmaceutical's profitability, liquidity, and operating efficiency, Rekah Pharmaceutical Industry is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Rekah Pharmaceutical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Rekah Pharmaceutical has an asset utilization ratio of 60.39 percent. This suggests that the Company is making 0.6 for each dollar of assets. An increasing asset utilization means that Rekah Pharmaceutical Industry is more efficient with each dollar of assets it utilizes for everyday operations.Rekah Pharmaceutical Ownership Allocation
The market capitalization of Rekah Pharmaceutical is 193.93 Million. Rekah Pharmaceutical has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with substantial debt, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.Rekah Pharmaceutical Profitability Analysis
The company reported the revenue of 263.95 M. Net Income was 6.62 M with profit before overhead, payroll, taxes, and interest of 65.16 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Rekah Pharmaceutical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Rekah Pharmaceutical and how it compares across the competition.
About Rekah Pharmaceutical Valuation
The stock valuation mechanism determines Rekah Pharmaceutical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Rekah Pharmaceutical. We calculate exposure to Rekah Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rekah Pharmaceutical's related companies.Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.
8 Steps to conduct Rekah Pharmaceutical's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Rekah Pharmaceutical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Rekah Pharmaceutical's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Rekah Pharmaceutical's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Rekah Pharmaceutical's revenue streams: Identify Rekah Pharmaceutical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Rekah Pharmaceutical's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Rekah Pharmaceutical's growth potential: Evaluate Rekah Pharmaceutical's management, business model, and growth potential.
- Determine Rekah Pharmaceutical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Rekah Pharmaceutical's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |